.png)
Sublingual Immunotherapy (SLIT) sets a benchmark in allergy treatment with its proven safety and clinical efficacy. Grounded in extensive research, AlleRx offers a transformative solution that significantly improves patient quality of life while adhering to the highest safety standards.
A study led by Edwin Kim, MD, at the UNC School of Medicine, focused on children aged 1 to 4 years, demonstrated the safety and efficacy of peanut SLIT. This study reported almost 80% of toddlers treated with peanut SLIT could tolerate 15 peanuts without allergic symptoms after treatment, showcasing its potential in inducing desensitization.
Importantly, it was also shown that 63% of the participants maintained their protection three months after stopping the treatment, indicating a lasting benefit
A phase 2 clinical trial over four years elucidated that an increased dosage continued to show promise for children, reinforcing the desensitization effect against peanuts. The trial revealed that 70% of participants showed protection against accidental exposures of peanut (greater than 800 mg, approximately 3 peanuts), and 36% exhibited full desensitization (5000 mg of peanut, about 16 peanuts).
The enhanced safety profile was evident, with only 4% of doses causing side effects, predominantly a temporary itch in the mouth, and no side effects necessitated treatment with epinephrine.
